Michels AA, et al. (2010) mTORC1 directly phosphorylates and regulates human MAF1. Mol Cell Biol 30, 3749-57 20516213

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S60-p - MAF1 (human) ▲

Modsite: PHVLEALsPPQtsGL SwissProt Entrez-Gene Orthologous residues MAF1 (human): S60‑p, MAF1 (mouse): S60‑p, MAF1 (rat): S60‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  HeLa (cervical) [MAF1 (human), transfection], IMR90hTERT (fibroblast) [MAF1 (human), transfection], MEF (fibroblast) [MAF1 (human), transfection] Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE mTOR (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes serum_starvation decrease rapamycin decrease Torin1 decrease MMS decrease Downstream Regulation Effect of modification (function):  activity, inhibited Effect of modification (process):  transcription, induced

T64-p - MAF1 (human) ▲

Modsite: EALsPPQtsGLsPsR SwissProt Entrez-Gene Orthologous residues MAF1 (human): T64‑p, MAF1 (mouse): T64‑p, MAF1 (rat): T64‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MMS no change compared to control no significant change

S65-p - MAF1 (human) ▲

Modsite: ALsPPQtsGLsPsRL SwissProt Entrez-Gene Orthologous residues MAF1 (human): S65‑p, MAF1 (mouse): S65‑p, MAF1 (rat): S65‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MMS no change compared to control no significant change

S68-p - MAF1 (human) ▲

Modsite: PPQtsGLsPsRLsks SwissProt Entrez-Gene Orthologous residues MAF1 (human): S68‑p, MAF1 (mouse): S68‑p, MAF1 (rat): S68‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  HeLa (cervical) [MAF1 (human), transfection], IMR90hTERT (fibroblast) [MAF1 (human), transfection], MEF (fibroblast) [MAF1 (human), transfection] Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE mTOR (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MMS decrease serum_starvation decrease rapamycin decrease Torin1 decrease Downstream Regulation Effect of modification (function):  activity, inhibited Effect of modification (process):  transcription, induced

S70-p - MAF1 (human) ▲

Modsite: QtsGLsPsRLsksQG SwissProt Entrez-Gene Orthologous residues MAF1 (human): S70‑p, MAF1 (mouse): S70‑p, MAF1 (rat): S70‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MMS decrease

S75-p - MAF1 (human) ▲

Modsite: sPsRLsksQGGEEEG SwissProt Entrez-Gene Orthologous residues MAF1 (human): S75‑p, MAF1 (mouse): S75‑p, MAF1 (rat): S75‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  HeLa (cervical) [MAF1 (human), transfection], IMR90hTERT (fibroblast) [MAF1 (human), transfection], MEF (fibroblast) [MAF1 (human), transfection] Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE mTOR (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MMS decrease serum_starvation decrease rapamycin decrease Torin1 decrease Downstream Regulation Effect of modification (function):  activity, inhibited Effect of modification (process):  transcription, induced

T212-p - MAF1 (human) ▲

Modsite: SISGSTYtPsEAGNE SwissProt Entrez-Gene Orthologous residues MAF1 (human): T212‑p, MAF1 (mouse): T212‑p, MAF1 (rat): T212‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MMS increase

S214-p - MAF1 (human) ▲

Modsite: SGSTYtPsEAGNELD SwissProt Entrez-Gene Orthologous residues MAF1 (human): S214‑p, MAF1 (mouse): S214‑p, MAF1 (rat): S214‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MMS decrease